nach oben

Cancer Chemotherapy and Pharmacology

Erschienen in:

22.11.2016 | Review Article

On-treatment markers as predictors to guide anti-EGFR MoAb treatment in metastatic colorectal cancer: a systematic review with meta-analysis

verfasst von: Jing Hu, Zhen Zhang, Rui Zheng, Lei Cheng, Mi Yang, Li Li, Baorui Liu, Xiaoping Qian

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Skin toxicity (ST) and early tumor shrinkage (ETS) are early phenomenon during the anti-epidermal growth factor receptor (EGFR) monoclonal antibody (MoAb) treatment. We conducted a meta-analysis and included relevant studies that reported the impact of ST and ETS on survival- and life quality-based outcome of metastatic colorectal cancer (mCRC) patients treated with anti-EGFR MoAb.

Methods

Relevant studies were identified from PubMed and Embase reporting the correlation of ST and ETS with the clinical outcome of mCRC patients treated with anti-EGFR MoAb. We also collected evidences on the impact of ST and ETS on absolute benefit acquired from additional anti-EGFR treatment and quality of life (ST only). Pooled hazard ratio and rate difference were all estimated by using random-effects model.

Results

Pooled data revealed that the occurrence of ST and ETS ≥20% (v < 20%) during anti-EGFR MoAb treatment were both associated with better OS, PFS and ORR. This association could not be disturbed by KRAS status. Mean changes in safety follow-up life health state from baseline appeared unaffected by ST. Only mCRC patients with wild-type KRAS tumor who suffered grade 2+ ST could benefit from additional anti-EGFR treatment to chemotherapy or best supportive care (BSC) alone. ETS was also a predictor for absolute survival benefit acquired from additional anti-EGFR treatment for patients with wild-type KRAS tumors, and the more early shrinkage the tumor was, the much benefit was observed.

Conclusion

ST and ETS are predictive of absolute benefit acquired from anti-EGFR treatment in mCRC patients with wild-type KRAS tumors. These two on-treatment markers can be used for clinical decision-making if no adequate biological markers from tissues are provided.

Nur mit Berechtigung zugänglich

Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA 61:69–90PubMed

Wolpin BM, Bass AJ (2014) Managing advanced colorectal cancer: have we reached the PEAK with current therapies? J Clin Oncol 32:2200–2202CrossRefPubMed

Woo J, Palmisiano N, Tester W et al (2013) Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer. Cancer 119:1941–1950CrossRefPubMed

Cheng L, Ren W, Xie L et al (2014) Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories. Cancer Chemother Pharmacol 74:1–13CrossRefPubMed

Scartozzi M, Galizia E, Chiorrini S et al (2009) Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 20:227–230CrossRefPubMed

Stintzing S, Kapaun C, Laubender RP et al (2013) Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group. Int J Cancer 132:236–245CrossRefPubMed

Peeters M, Siena S, Van Cutsem E et al (2009) Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer 115:1544–1554CrossRefPubMed

Piessevaux H, Buyse M, Schlichting M et al (2013) Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 31:3764–3775CrossRefPubMed

Suzuki C, Blomqvist L, Sundin A et al (2012) The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy. Ann Oncol 23:948–954CrossRefPubMed

10.

Ottawa Hospital Research Institute. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Accessed 23 Aug 2012

11.

Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12CrossRefPubMed

12.

Moher D, Liberati A, Tetzlaff J et al (2010) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 8:336–341CrossRefPubMed

13.

Higgins JP, Thompson SG, Deeks JJ et al (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560CrossRefPubMedPubMedCentral

14.

Egger M, Davey Smith G, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634CrossRefPubMedPubMedCentral

15.

Ye LC, Liu TS, Ren L et al (2013) Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol 31:1931–1938CrossRefPubMed

16.

Vincenzi B, Santini D, Rabitti C (2006) Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. Br J Cancer 94:792–797CrossRefPubMedPubMedCentral

17.

Van Cutsem E, Peeters M, Siena S et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658–1664CrossRefPubMed

18.

Vallbohmer D, Zhang W, Gordon M et al (2005) Molecular determinants of cetuximab efficacy. J Clin Oncol 23:3536–3544CrossRefPubMed

19.

Thaler J, Karthaus M, Mineur L et al (2012) Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study. BMC Cancer 12:438CrossRefPubMedPubMedCentral

20.

Sommeijer DW, Karapetis CS, Zalcberg JR et al (2014) The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17. Acta Oncol 53:877–884CrossRefPubMed

21.

Sohn BS, Kim TW, Lee JL et al (2009) The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients. Oncology 77:224–230CrossRefPubMed

22.

Racca P, Fanchini L, Caliendo V et al (2008) Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: outcomes from an oncologic/dermatologic cooperation. Clin Colorectal Cancer 7:48–54CrossRefPubMed

23.

Peeters M, Price TJ, Cervantes A et al (2014) Final results from a randomized phase 3 study of FOLFIRI ±}{Hawkes, 2010 #124 panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol 25:107–116CrossRefPubMed

24.

Park JH, Han SW, Oh DY et al (2011) Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer. Cancer Chemother Pharmacol 68:1045–1055CrossRefPubMed

25.

Paez D, Pare L, Espinosa I et al (2010) Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy? Cancer Sci 101:2048–2053CrossRefPubMed

26.

Muro K, Yoshino T, Doi T et al (2009) A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol 39:321–326CrossRefPubMed

27.

Lievre A, Bachet JB, Boige V et al (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26:374–379CrossRefPubMed

28.

Levi F, Karaboue A, Gorden L et al (2011) Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability. Cancer Chemother Pharmacol 67:339–348CrossRefPubMed

29.

Lenz HJ, Van Cutsem E, Khambata-Ford S et al (2006) Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 24:4914–4921CrossRefPubMed

30.

Lelli G, Cataldo S, Carandina I et al (2008) The role of cetuximab in pre-treated refractory patients with metastatic colorectal cancer: outcome study in clinical practice. J Chemother 20:374–379CrossRefPubMed

31.

Kogawa T, Doi A, Shimokawa M et al (2014) Early skin toxicity predicts better outcomes, and early tumor shrinkage predicts better response after cetuximab treatment in advanced colorectal cancer. Target Oncol 10:125–133CrossRefPubMed

32.

Jonker DJ, O’Callaghan CJ, Karapetis CS et al (2007) Cetuximab for the treatment of colorectal cancer. New Engl J Med 357:2040–2048CrossRefPubMed

33.

Jehn CF, Boning L, Kroning H et al (2012) Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer. Br J Cancer 106:274–278CrossRefPubMedPubMedCentral

34.

Gamucci T, Nelli F, Cianci G et al (2008) A phase II study of cetuximab/irinotecan in patients with heavily pretreated metastatic colorectal cancer: predictive value of early specific toxicities. Clin Colorectal Cancer 7:273–279CrossRefPubMed

35.

Douillard JY, Siena S, Cassidy J et al (2014) Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol 25:1346–1355CrossRefPubMed

36.

Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. New Engl J Med 351:337–345CrossRefPubMed

37.

Carrato A, Gomez A, Escudero P et al (2013) Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer. Clin Transl Oncol 15:705–711CrossRefPubMed

38.

Modest DP, Laubender RP, Stintzing S et al (2013) Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: an analysis of the German AIO KRK 0104 trial. Acta Oncol 52:956–962CrossRefPubMed

39.

Petrelli F, Borgonovo K, Barni S (2013) The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials. Target Oncol 8:173–181CrossRefPubMed

40.

Hawkes E, Cunningham D (2010) Relationship between colorectal cancer biomarkers and response to epidermal growth factor receptor monoclonal antibodies. J Clin Oncol 28:529–531CrossRef

41.

Schirripa Marta, Cremolini Chiara, Loupakis Fotios et al (2015) Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. Int J Oncol 136:83–90

42.

Seligmann Jenny F, Elliott Faye, Richman Susan D et al (2016) Combined epiregulin and amphiregulin expression levels as a predictive biomarker for panitumumab therapy benefit or lack of benefit in patients with ras wild-type advanced colorectal cancer. JAMA Oncol 2:633–642CrossRef

43.

Llovet Patricia, Sastre Javier, Ortega Julián Sanz et al (2015) Prognostic value of BRAF, PI3 K, PTEN, EGFR copy number, amphiregulin and epiregulin status in patients with KRAS Codon 12 wild-type metastatic colorectal cancer receiving first-line chemotherapy with Anti-EGFR therapy. Mol Diagn Ther 19:397–408CrossRefPubMed

44.

Oxnard GR, Schwartz LH (2013) Response phenotype as a predictive biomarker to guide treatment with targeted therapies. J Clin Oncol 31:3739–3741CrossRefPubMed

45.

Grothey A, Hedrick EE, Mass RD et al (2008) Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol 26:183–189CrossRefPubMed

46.

Van Cutsem E, Tejpar S, Vanbeckevoort D et al (2012) Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J Clin Oncol 30:2861–2868CrossRefPubMed

Titel: On-treatment markers as predictors to guide anti-EGFR MoAb treatment in metastatic colorectal cancer: a systematic review with meta-analysis
verfasst von: Jing Hu
Zhen Zhang
Rui Zheng
Lei Cheng
Mi Yang
Li Li
Baorui Liu
Xiaoping Qian
Publikationsdatum: 22.11.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 2/2017
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-016-3196-2

Neu im Fachgebiet Onkologie

16.04.2024 | Maligne primäre ZNS-Tumoren | Nachrichten

Springer Medizin

On-treatment markers as predictors to guide anti-EGFR MoAb treatment in metastatic colorectal cancer: a systematic review with meta-analysis

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)

Single-center comparison of multiple chemotherapy regimens for concurrent chemoradiotherapy in unresectable stage III non-small-cell lung cancer

Use of retinoic acid/aldehyde dehydrogenase pathway as potential targeted therapy against cancer stem cells

Myeloprotective effects of C-type natriuretic peptide on cisplatin-induced bone marrow granulocytopenia in mice

Ionotropic glutamate receptor antagonists and cancer therapy: time to think out of the box?

Trends on polymer- and lipid-based nanostructures for parenteral drug delivery to tumors

Neu im Fachgebiet Onkologie

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Update Onkologie